The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving Oxaliplatin-based chemotherapy: A meta-analysis based on 22 studies

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8383-8390

  Qian, Ying Ying ^a   Liu, Xin You ^a   Wu, Qian ^a   Song, Xian ^a   Chen, Xiao Feng ^a   Liu, Yi Qian ^a   Pei, Dong ^a   Shen, Li Zong ^a   Shu, Yong Qian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; ERCC1; Meta analysis; Oxaliplatin; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; OXALIPLATIN; PLATINUM COMPLEX;

COLORECTAL NEOPLASMS; GENETIC POLYMORPHISM; GENETICS; HUMAN; META ANALYSIS; MORTALITY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84908389391     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8383     Document Type: Article

References (49)

1. Ahmad S (2010). Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers, 7, 543-66.
2. Alberts SR, Horvath WL, Sternfeld WC, et al (2005). Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol, 23, 9243-9.
3. Altman DG, Bland JM (2003). Interaction revisited: the difference between two estimates. BMJ, 326, 219.
4. Boige V, Mendiboure J, Pignon JP, et al (2010). Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol, 28, 2556-64.
5. Braun MS, Richman SD, Quirke P, et al (2008). Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol, 26, 2690-8.
6. Cassidy J, Clarke S, Diaz-Rubio E, et al (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol, 26, 2006-12.
7. Chai H, Pan J, Zhang X, et al (2012). ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int J Clin Exp Med, 5, 186-94.
8. Chang PM, Tzeng CH, Chen PM, et al (2009). ERCC1 codon 118 C-->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci, 100, 278-83.
9. Chen YC, Tzeng CH, Chen PM, et al (2010). Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 101, 530-5.
10. Cheng J, Ha M, Wang Y, et al (2012). A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol, 138, 231-8.
11. Chua W, Goldstein D, Lee CK, et al (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer, 101, 998-1004.
12. Cortejoso L, Garcia MI, Garcia-Alfonso P, et al (2013). Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol, 71, 1463-72.
13. Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37.
14. Fakih MG, Bullarddunn K, Yang GY, et al (2008). Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys, 72, 650-7.
15. Farina Sarasqueta A, van Lijnschoten G, Lemmens VE, et al (2011). Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther, 15, 277-83.
16. Huang MY, Huang ML, Chen MJ, et al (2011). Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics, 21, 18-25.
17. Inada M, Sato M, Morita S, et al (2010). Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther, 48, 729-34.
18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
19. Kang S, Sun HY, Zhou RM, et al (2013). DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy. Asian Pac J Cancer Prev, 14, 941-6.
20. Kumamoto K, Ishibashi K, Okada N, et al (2013). Polymorphisms of , and -3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett, 6, 648-54.
21. Kwon HC, Roh MS, Oh SY, et al (2007). Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18, 504-9.
22. Lamas MJ, Duran G, Balboa E, et al (2011). Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 12, 433-42.
23. Lee KH, Chang HJ, Han SW, et al (2013). Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol, 71, 843-51.
24. Li H-Y, Ge X, Huang G-M, et al (2012). GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev, 13, 3465-9.
25. Liang J, Jiang T, Yao RY, et al (2010). The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol, 66, 493-500.
26. Liang J, Lv H, Yao R, et al (2008). ERCC1 Asn118Asn polymorphism as predictor for cancer response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Chinese-German J Clin Oncol, 7, 455-9.
27. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.
28. Martinez-Balibrea E, Abad A, Aranda E, et al (2008). Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer, 44, 1229-37.
29. Moreno V, Gemignani F, Landi S, et al (2006). Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res, 12, 2101-8.
30. Nishina T, Takano Y, Denda T, et al (2013). A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol, 43, 1080-6.
31. Noda E, Maeda K, Inoue T, et al (2012). Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/ oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology, 59, 130-3.
32. Oguri T, Mitsuma A, Inada-Inoue M, et al (2013). Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int J Clin Pharmacol Ther, 51, 475-81.
33. Pare L, Marcuello E, Altes A, et al (2008). Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer, 99, 1050-5.
34. Raymond E, Chaney SG, Taamma A, et al (1998). Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 9, 1053-71.
35. Reed E (2005). ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2.
36. Ruzzo A, Graziano F, Loupakis F, et al (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol, 25, 1247-54.
37. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41.
38. Spindler KL, Andersen RF, Jensen LH, et al (2010). EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol, 21, 535-9.
39. Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
40. Sun XH, Hou WG, Zhao HX, et al (2013). Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pac J Cancer Prev, 14, 2049-52.
41. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.
42. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16.
43. Viguier J, Boige V, Miquel C, et al (2005). ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res, 11, 6212-7.
44. Vilmar A, Sorensen JB (2009). Excision repair crosscomplementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, 64, 131-9.
45. Woelfelschneider A, Popanda O, Lilla C, et al (2008). A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis, 29, 1758-64.
46. Yang J, Wang ZG, Cai HQ, et al (2013). Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev, 14, 4595-8.
47. Yin M, Yan J, Martinez-Balibrea E, et al (2011). ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res, 17, 1632-40.
48. Yue AM, Xie ZB, Zhao HF, et al (2013). Associations of ABCB1 and XPC genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis in a Chinese population. Asian Pac J Cancer Prev, 14, 3085-91.
49. Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6.